Non natural amino acids as potential antimicrobial agents: Synthesis of an analogue of anticapsin and diketopiperazine scaffolds by Pes, Lara
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1.1-  Antimicrobial agents 
 
Compounds that eliminate or inhibit the development of bacteria, fungi, parasites or 
viruses  are  called  antimicrobials  and  respectively  referred  to  as  antibacterial, 
antifungal,  antiprotozoal  and  antiviral  agents.
[1]    These  chemicals  used  to  treat 
infectious  diseases  fall  into  two  main  categories,  namely  natural  products  and 
chemotherapeutic agents.  Natural products are secondary metabolites that are only 
generated  by  certain  microorganisms  and  are  usually  large,  elaborated  organic 
molecules  that  require  complex  enzymatic  synthesis.
[2]    Alternately  the  group  of 
chemotherapeutic  agents  comprise  of  compounds  that  have  been  synthesised 
chemically.  A hybrid of these two categories exists, in which natural products that 
have been chemically modified to alter particular characteristics and is referred to as 
semi-synthetic antimicrobials.   
Numerous antimicrobial agents are known; however, not all of them can be used in 
vivo as in addition to their antimicrobial activity they can be toxic to human beings.
[3] 
Antimicrobials  have  to  be  non-toxic,  non-allergenic,  effective  and  selective, 
chemically  stable,  active  against  possibly  more  than  one  bacterium  and 
inexpensive.
[1]  The ratio between the therapeutic effect and the toxic effect in the 
human body is described by the drugs therapeutic index (TI).
[4]  
Antimicrobial  drugs  (Figure  1.1)  can  have  several  different  modes  of  action.  
Penicillins (1) and cephalosporins (2) act by interfering with the synthesis of cell 
wall, while tetracyclines (3), macrolides (4), aminoglycosides (5) and phenicols (6) 
interrupt  the  synthesis  of  proteins  and  sulfonamides  (7)  and  fluoroquinolones  (8) 
obstruct DNA functions.
[5] 
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Figure 1.1: Antimicrobial drugs: penicillin (1); cephalosporin (2); the 4 rings of the basic tetracycline 
structure (3); clarithromycin, example of macrolide (4); streptomicyn, example of aminoglycoside (5); 
chloramphenicol (6); sulfonamine structure (7); fluoro-quinolone (8). 
 
Antibacterial agents usually act by modifying the structure or the metabolic pathways 
of bacteria.  This may be achieved via the creation of a bond with the cytoplasmic 
membrane,  through  inhibition  of  protein  or  nucleic  acid  biosynthesis  or  by 
interference with cell wall synthesis.
[6] 
The  group  of  antibacterial  agents  comprise  of  antibiotics,  disinfectants  and 
antiseptics.  Unlike disinfectants and antiseptics, antibiotics exhibit selective toxicity 
and exploit the biochemical features which differ in the host and in the parasites, 
damaging the microorganism, but leaving the host undamaged.
[7]  Disinfectants kill 3 
 
bacteria but are unselective and can be toxic for mammals and are not used in vivo. 
Antiseptics are less poisonous: they are used topically but are toxic if ingested.  
Bacteria are classified as either Gram-positive or Gram-negative as determined by 
the result of the Gram stain.  Gram-positive bacteria have a thick peptidoglycan layer 
within the cell wall, so upon staining they became dark blue or violet.  Conversely 
Gram-negative  bacteria  have  only  a  thin  peptidoglycan  layer  and  a  further  outer 
membrane so they are rapidly decolorised by the stain becoming red or pink.  This 
additional  outer  membrane  gives  Gram-negative  bacteria  a  higher  resistance  to 
antibiotics.
[2]  Antibacterial agents can be classified on the basis of the number of 
bacteria they are active against. Those active against both Gram-positive and Gram-
negative bacteria are named “broad spectrum”, while those active against only one 
kind  of  bacteria  are  named  “narrow  spectrum”  and  those  active  against  only  an 
organism are named “limited spectrum”.
[8] 
There are two possible modes of action of antibiotics.  Bactericidal antibiotics, for 
example  penicillin  (1),  act  by  either  killing  (or  cleaving)  the  invading  organism, 
while bacteriostatic antibiotics, for example chloramphenicol (8), are only able to 
limit bacterial growth and replication.
[3,5] 
In the 19
th century the study of antibacterial agents became a topic of great interest 
and the most important breakthrough was the discovery of penicillin (1).  Several 
researchers had observed that aerated LB media in the presence of penicillium mould 
became  much  less  turbid  than  that  which  was  not  exposed  to  the  mould.    The 
Scottish bacteriologist Alexander Fleming was the first to understand that this was 
due to the antibacterial property of penicillin (1). 
In the 1920s, Fleming realised that the penicillium mould modified the shape of the 
colonies of Staphylococcus sp. and from this deduced that penicillium mould had 
antimicrobial  activity.    He  purified  and  studied  the  substance  isolated  from  the 
mould,  penicillin  (1),  and  found  that  it  inhibited  certain  bacterial  cultures. 
Importantly  it  including  Staphylococcus  sp.,  Streptococcus  pyrogenes  and 
Pneumococcus sp. cultures, was non toxic if used on human tissues.  Penicillin (1) 
was administered as antibacterial agent for the first time in 1940s.
[9] 
Penicillin (1) and Cephalosporin (2), isolated from Cephalosporium moulds, contain 
planar  4-membered  beta-lactam  compounds,  joined  to  another  larger  ring.    They 
inhibit the synthesis of bacterial cell walls, which are fundamental for the growth of 4 
 
bacteria.  These  cell  walls  mainly  comprise  of  peptidoglycan,
[6,2]  formed  by 
polysaccharide cross-linked chains of alternated N-acetyl-muramic acid (NAM, 9) 
and  N-acetyl-glucosamine  (NAG,  10)  providing  chemical  stability,  mechanical 
strength and rigidity, as shown in Figure 1.2.  The beta-lactams, irreversibly bind to 
the enzyme as a “suicide inhibitor”.  Eukaryotes do not have peptidoglycans in their 
cell walls, so they cannot bind these drugs, which have little or no toxicity for human 
beings. 
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Figure 1.2: Peptidoglycan structure of bacterial cell wall with N-acetyl-muramic acid (NAM, 9) and 
N-acetyl-glucosamine (NAG, 10).
[10] 
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1.2-  Bacilysin & anticapsin  
 
The  dipeptide  antibiotic  bacilysin  (11),  shown  in  Figure  1.3,  also  referred  to  as 
tetaine or L-alanyl-(2,3-epoxycyclohexanone-4)-L-alanine, was discovered in 1949 in 
Oxford.  It was one of the first identified examples of a natural pro-drug and one of 
the  simplest  peptide  antibiotics  known.    In  1987  Woynarowska  reported  on  the 
anticancer  activity  of  bacilysin  (11).    The  reduced  growth  of  tumor  cells  was 
presumed to be the effect of impairing DNA and RNA synthesis.
[11] 
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Figure 1.3: Bacilysin (11), a simple dipeptide antibiotic. 
 
Bacilysin (11) is produced and excreted by certain strains of Bacillus subtilis A14, a 
Gram-positive, catalase-positive bacterium commonly found in soil.
[12, 13, 14,15] Bacilli 
produce a broad spectrum of secondary metabolites, the majority of which are small 
peptides with unusual components, synthesised non-ribosomally.
[16,17] 
The structure of bacilysin (11) in conjunction with its broad spectrum antibacterial 
and antifungal activity was established by Walker and Abraham in 1970.
[17-19]  A 
dipeptide  transport  system  carries  bacilysin  (11)  into  the  microorganism,  where 
intracellular peptidases hydrolyse it to produce L-anticapsin (12). and L-alanine (13) 
as shown in Scheme 1.1.
[12,17] 6 
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Scheme 1.1: The intercellular hydrolysis of bacilysin (11) from which L-anticapsin (12) and L-alanine 
(13) are produced. 
 
Anticapsin (12) is a fermentation product and biologically active metabolite isolated 
from the culture filtrate of Streptomyces griseoplanus.  It was discovered in 1970 by 
the Lilly Research Laboratories (Eli Lilly and Co., Indianapolis, USA) as an epoxy-
keto-amino acid, C-terminal residue of bacilysin (11).
[13, 20, 21]  
Anticapsin (12) limits the formation of the hyaluronic acid capsules (14), shown in 
Figure 1.4, in Streptococcus pyogenes.   
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Figure 1.4: Hyaluronic acid (14) 
 
Streptococcus pyogenes, shown in Figure 1.5, is a group A streptococcus (GAS) and 
Gram-positive  bacterium.    It  is  a  very  important  human  pathogen  that  causes  a 
particularly  wide  spectrum  of  infections.  GAS  colonises  the  skin  and  mucosal 
surfaces and can lead to several diseases, skin or throat infections as well as more 
dangerous,  life-threatening  disorders,  including  necrotizing  fasciitis,  streptococcal 
toxics and Hock syndrome.  These lead to complications including rheumatic fever, 
rheumatic heart disease and acute glomerulo nephritis.  The capacity of GAS to adapt 
and persist at a numerous tissue sites means this pathogen can be very dangerous.
[22] 7 
 
 
 
Figure 1.5: Streptococcus pyogenes: .a) Colonies of Streptococcus pyogenes on blood agar exhibiting 
beta (clear) hemolysis; and b) Streptococcus pyogenes bacteria at 900x magnification. 
 
A synthetic route to synthesise anticapsin (12) was reported by Baldwin et al., and is 
shown in Scheme 1.2:
[23] 
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Reagents and conditions: i)  TBDPSCI, imidazole, DMF; ii) KOSiMe3, benzene, reflux, 1.5 h, acidic 
work-up  [NH4CI  (sat.  aq. soln.)]; iii)  oxalyl  chloride,  DMF,  toluene  -5 °C  to 10 °C  45 mins;  
sodium  2-mercapto  pyridine-N-oxide, DMAP,  benzene,  30 mins  at  r.t., addition  of  tert-
dodecanethiol,  hv  (200 W  tungsten  lamp)  20 °C-3 °C  2.5 h;  iv) Ts-H20, THF-H20,  24 h,  r.t.;  v)  
MsCI,  pyridine,  19 h,  r.t.;  vi)  Nal,  acetone,  reflux,  21 h;  vii)  (2R)-2,5-dihydro-2-isopropyl-3,6-
dimethoxypyrazine,  nBuLi,  THF,  -78°C;  CuCN,  2 mins,  0 °C,  -78°C  then  -21°C; -21 °C 24 h; 
viii)  0.25 M  HCI (aq),  CH3CN 100 mins,  r.t.;  acetic  anhydride,  pyridine  1.75 h,  r.t.; ix) NH4F,  
MeOH,  50 °C 18 h;  x)  mCPBA,  CHCI3,  2 h,  r.t.; xi) TPAP,  N-methyl  morpholine-N-oxide, 
CH3CN  , 1 h, r.t; xii)  pronase  E, phosphate  buffer  [~2:3 ratio  of  0.1 M KD2PO4  and 0.1 M 
Na2DPO 4 in D20] pH 7.5, 30 °C,  3 h;  acylase  I from  sp. aspergillus immobilised  on  eupergrit  C, 
phosphate  buffer [~2:3  ratio of 0.1 M KD2PO4  and 0.1 M Na2DPO4  in D2O]  pH 7.5, 30 °C  30 h 
then  cellulose  chromatography  (80 % aqueous  propan-2-ol  as eluent). 
Scheme 1.2: Stereocontrolled  enantiospecific  synthesis  of the  revised structure of anticapsin (12): 9 
 
 
Anticapsin (12) acts as L-glutamine (15, figure 1.6) analogue, inhibiting Glucosamin-
6-phosphate  synthase  (GlcN-6-PS),  an  enzyme  also  referred  to  as  L-glutamine-D-
fructose-6-phosphate amidotransferase. This enzyme is essential in the synthesis of 
peptidoglycan cell walls in bacteria and chitin cell walls in fungi.
[17,19,24,25]  Inhibition 
of this enzyme results in weakening of the cell walls.  High internal osmotic pressure 
leads to lysis of the cell.
[23]  Anticapsin (12) has been reported to strongly inhibit the 
synthesis of GluN-6-PS enzyme in E. coli and Staphylococcus aureus.  Anticapsin 
(12) inhibition has also been demonstrated in the cell-free extracts from bacteria, 
yeast and tumor cells.
[12,24] 
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Figure 1.6: L-glutamine (15)  
 
Wojciechowski et al., superimposed two diasteroisomers of anticapsin (12) differing 
only at the Cg-carbon in order to understand the importance of the stereochemistry at 
the  g  position,  as  shown  in  Figure  1.7.  The  R-isomer  (12-R)  did  not  show  any 
significant activity with GlcN-6-PS, while the S-isomer (12-S) has shown to be a 
potent inhibitor of the enzyme.  
To date, there have been no studies involving the altering of the stereochemistry of 
the epoxide or at the amine moiety to see if the change affects the activity. 10 
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Figure 1.7: Orthogonal view of the superimposition of two diasteroisomers of anticapsin (12) Cg R-
isomer (12-R) and Cg S-isomer (12-S). 
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Glucosamine-6-phosphate synthase  
 
 
Figure 1.8: Glucosamine 6-phosphate synthase (GlcN-6-PS).
[26] 
 
GlcN-6-PS, shown in Figure 1.8, is essential in the synthesis of peptidoglycan cell 
walls in bacteria and chitin cell walls in fungi.
[17,19,24,25]  GlcN-6-PS catalyses the 
conversion  of  fructose  6-phosphate  (Fru-6-P,  16)  into  glucosamine  6-phosphate 
(Glu-6-P, 17) where glutamine (15), utilised as nitrogen source, is converted into 
glutamic acid (18), as shown in Scheme 1.3.
[27] 
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Scheme 1.3: The GlcN-6-PS catalysed conversion of glutamine (15) and fructose 6-phosphate (16) 
into glucosamine 6-phosphate (17) and glutamic acid (18) respectively. 
 
Amidotransferases, shown in Figure 1.9, use the nitrogen of the amide of glutamine 
(15)  molecule  in  several  biosynthetic  reactions  (example  of  substrates  are  amino 
acids,  carbohydrates  and  nucleotides).    Amidotransferases  contain  two  principal 
domains, namely a glutaminase domain, responsible of the hydrolysis of glutamine 
(15) to glutamic acid (18) and an ammonia, and synthetase (or synthase) domain, 
responsible of the amination of the substrate.
[28,29] 
 12 
 
 
Figure 1.9: General amidotransferase structure.
[27] 
 
In E. coli the enzyme structure confirms the usual homodimeric organization of the 
molecule. A 18 Ǻ hydrophobic channel joins the domains and allows the passage of 
ammonia. This transfer is also permitted by a C-terminal decapeptide between the 
domains.
[27]   
 
 
Mechanism of action of anticapsin  
 
As  previously  mentioned,  anticapsin  (12)  inhibits  GlcN-6-PS  in  Streptococcus 
Pyogenes, by acting as an analogue of glutamine (15). This enzyme is implicated in 
the initial step of the biosynthesis of a precursor of the hyaluronic acid (14), named 
uridine  diphosphate-N-  acetyl  glucosamine  (UDP-NAcGlc,  19),  shown  in  Figure 
1.10. Anticapsin (12), inhibiting the enzyme, inhibits the formation of hyaluronic 
acid (14) capsules resulting in bacterial cell death.
[24] 
Hyaluronic acid (14) is a polysaccharide composed by D-glucuronic acid and D-N-
acetyl-glucosamine, alternating β-1,4 and β-1,3 glycosidic bonds (Figure 1.4). The 
hyaluronic acid (14) capsules are involved in the virulence of the organism and make 
the bacteria resistant to attack by bacteriophage, allowing it to go unnoticed by the 
immune system.
[21,30] 
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Figure 1.10: Uridine diphosphate-N-acetyl glucosamine (19). 
 
 
The main step in the biosynthesis of Glu-6-P (17), shown in Scheme 1.4, is the attack 
of  the  thiol  side-chain  of  an  active  site  cysteine  of  glucosamine  synthase,  to  the 
carbonyl carbon of the glutamine (15).  The ammonia generated from this reaction 
then reacts with the keto-group of Fru-6-P (16). After rearrangement of the imine 
(21), Glu-6-P (17) is formed and the thioester (20) is hydrolyzed to regenerate the 
active site and glutamic acid (18). 
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Scheme 1.4: Mechanism of formation of Glu-6-P (17). 
 
The thiol group of active site cysteine of glucosamine synthase attacks its carbonyl 
carbon  through  nucleophilic  addition,  resulting  in  an  irreversible  alkylation  after 
15  16  20  16 
21 
17 
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migration of the sulfur onto the a-carbon (22) and an intramolecular opening of the 
epoxide ring (23), as shown in Scheme 1.5.
[23,31] 
 
 
 
 
 
 
 
 
12 
Scheme 1.5: Mechanism of inactivation of GlcN-6-PS. 
 
This hypothetical mechanism was derived from theoretical studies on non-biological 
systems but not definite conclusion was drawn on the reactivity of the epoxyketone 
containing natural products in the presence of thiophenes derivatives. 
It has been shown that an equilibrium between anticapsin (12) and the hydrate form 
(S)-2-ammonio-3-((1R,2S,6R)-5,5-dihydroxy-7-oxa-bicyclo[4.1.0]heptan-2-
yl)propanoate (24) in aqueous solution exists (Scheme 1.6),
[23] which has been used 
to  rationalize  the  ketone  as  most  likely  site  of  nucleophilic  attack  in  other 
epoxyketones.
[31]   
cysteine
HS O
O
NH3
CO2
O
OH
S
cysteine
NH3
CO2
O
NH3
CO2
S
OH
cysteine
22  23 15 
 
 
O
NH3
COO
O
O
NH3
COO
HO OH
H2O
H=0.33
 
          12           24 
Scheme 1.6: Equilibrium between anticapsin (12) and its hydrate form (24). 
 
 
1.3-  Antibacterial resistance 
 
Antibiotics are still an important topic in research spanning several different fields, 
including human and veterinary medicine; animal feeds; agriculture; and the food 
industry.
[1]  The process to develop an antibiotic can be expensive and arduous, so 
often large pharmaceutical companies abandon the market.  Actions have to be taken 
against the spreading of infections.  It is desirable to improve the yields of synthetic 
pathways to existing antibacterial agents but it is also worth to try to find new agents.  
This is especially true for those microorganisms for which no antibacterial agent has 
yet been developed or for those that have developed antibacterial resistance.  The 
problem  of  the  antibacterial  resistance  requires  the  continuous  discovery  of  new 
compounds as it depends on numerous variables, including genetics factors, hormone 
levels, nutritional status.
[32]  
100,000 tons of antibiotics are synthesised worldwide annually.
[2]  The overuse of 
antibiotics, especially in the last two decades, has influenced the ecology of bacteria 
and over time bacteria have become resistant to them. In the beginning of the 1960s 
only 10 % of the bacterial strains were resistant to penicillin G, while in 2010 that 
number has come close to 100 %.
[6] Resistance may occur because of modification of 
the  active  site  of  the  target  enzyme,  incapability  for  the  antibiotic  to  access  and 
creation of enzymes that inactivate or destroy the antibiotic.  16 
 
One of the causes of antibacterial resistance is the modification that can occur at the 
gene level, resulting in a greater affinity for the substrate or a smaller affinity for the 
antibiotic.  The access of a substrate can be denied because of structural changes that 
altered for instance the permeability of the antibiotic through the bacterial membrane 
or because the alteration of the gene code provoke a mechanism of expulsion of the 
antibiotic. Another reason can be the lack of a particular structural moiety that the 
antibiotic needs in order to interact with the microorganism. Additionally, there is a 
strong  possibility  that  the  bacteria  can  evolve  active  mechanisms  to  destroy  or 
inactivating antibiotics. This has happened in the case of beta-lactams.
[2,6]   
The  random  modification  starts  when  a  very  tiny  number  of  bacteria  become 
genetically resistant to a given antibiotic.  If even in 100,000,000 cells, then that 
single  resistant  bacterium  will  not  die,  but  will  multiply,  generating  a  resistant 
progeny. With time, this new resistant population will take the place of the previous 
one.
[33] This capability of surviving increase significantly with the amount of bacteria 
treated and with the quantity of antibiotic utilised.  
Sometimes, resistance is not generated from a random mutation, but from the random 
acquisition of ‘resistance genes’.
[34]  17 
 
1.4-  Analogues of anticapsin 
 
For the reasons mentioned above (Section 1.3), this thesis will discuss and explain 
the synthesis of a novel antibacterial agent, (S)-2-ammonio-3-((1R,6R)-2-oxo-7-oxa-
3-aza-bicyclo[4.1.0]heptan-5-yl)propanoate (25), shown in Figure 1.11, an analogue 
of anticapsin (12).  
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Figure 1.11: (S)-2-ammonio-3-((1R,6R)-2-oxo-7-oxa-3-aza-bicyclo[4.1.0]heptan-5-yl)propanoate 
(25), analogue of anticapsin (12). 
 
The main difference between anticapsin (12) and the novel molecule (25) will be the 
introduction of a nitrogen atom into the ring. Nitrogen has been chosen to be inserted 
into the ring as it is a constituent of molecules in almost every major drug class used 
in  pharmacology  and  medicine,  including  Levaquin
®  (26),  Omnicef®  (27)  and 
Lamisil Oral® (28), shown in Figure 1.12. Levaquin® (26), a fluoroquinolones drug, 
is used to treat bacterial infections of the skin, sinuses, kidneys, bladder, or prostate 
and also to treat bacterial infections that cause bronchitis or pneumonia, and to treat 
people  who  have  been  exposed  to  anthrax.  Omnicef
®  (27)  is  a  cephalosporin 
antibiotic, used against acute flare-ups of chronic bronchitis, middle ear infections, 
throat and tonsil infections, pneumonia, sinus infections and skin infections. Lamisil 
Oral
®  (28),  is  an  antifungal  antibiotic  and  it  works  against  infections  caused  by 
fungus that affect the fingernails or toenails.
[35] 18 
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Figure1.12: Levaquin
® (26); Omnicef
® (27); Lamisil Oral
® (28). 
 
Nitrogen is present, not only in organic nitrate drugs like nitroglycerin (29), which is 
utilized in cardiovascular medicine,
[36] but also in drugs derived also from plant, such 
as alkaloids (30) and morphine (31), shown in Figure 1.13. 
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Figure 1.13: Nitroglicerine (29), ephedrine, example of alkaloid (30) and morphine (31). 
 
 
An example of analogue of anticapsin, (S)-3-((1R,2S,6S)-7-oxa-bicyclo[4.1.0]heptan-
2-yl)-2-ammoniopropanoate  (32),  shown  in  Figure  1.14,  has  been  synthesized  by 
Borowski and co-workers.
[37]  This is the anticapsin molecule (12) without the ketone 
moiety.  
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Figure 1.14: (S)-3-((1R,2S,6S)-7-oxa-bicyclo[4.1.0]heptan-2-yl)-2-ammoniopropanoate (32),  
analogue of anticapsin without the ketone moiety. 
 
A comparison of the activity of this analogue (32) with anticapsin (12), in E. coli, S. 
cerevisae and C. albicans, found that the keto group is not essential to inactivate the 
amidotransferase enzyme, but without it, the activity decreases significantly. So it is 
possible that the proposed mechanism of inhibition, shown in Scheme 1.5, is not 
accurate. The ketone may be essential for binding but not involved directly in the 
inhibition. Another possibility is that the hydrate (24) stabilises binding in the active 
site prior to inhibition or that this hydrate form does not exist within the active site. 
The target analogue (25) in Figure 1.11 was chosen with the aim of making an attack 
on the carbonyl and hydrolysis to form hydrate (24) less likely. 
The anticapsin analogue (25) is a non-natural amino acid that could be biologically 
tested and compared to anticapsin (12). 
This  kind  of  amino  acid,  even  if  not  present  in  nature,  can  play  a  vital  role  in 
understanding  important  protein  conformations  and  interactions,  really  useful  to 
design  peptide-based  therapeutic  drugs.  Once  in  the  protein,  natural  amino  acid 
analogues can help in identifying structural and functional domains, conformational 
changes and protein-protein interactions within the protein. 
In  order  to  synthesise  the  proposed  molecule  (25),  the  capability  of  the 
diketopiperazine  scaffold  (1,4-disubstituted  diketopiperazine  2,5-dione,  DKP,  33), 
shown in Figure 1.15, has been exploited to generate amino acid.  
 20 
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Figure 1.15: 1,4-disubstituted diketopiperazine 2,5-dione (33). 21 
 
The retrosynthetic route is shown in the Scheme 1.7.  
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Scheme 1.7: Retrosynthetic approach to the synthesis of the anticapsine analogue (25). 
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The starting materials (38, 39, 40) are commercially available and lead to the target 
activated compound after six steps. Once activated, compound (37) can be alkylated 
to the DKP scaffold (33) selectively. After deprotection and hydrolysis, the resulting 
amino  acid  can  be  selectively  epoxidised,  obtaining  the  desired  heterocyclic 
analogue. 
This work will be discussed in more detail in the following chapters. 
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2.1-  Aim  
 
The  aim  of  this  first  part  of  the  project  is  to  synthesise  1,4-disubstituted 
diketopiperazine 2,5-dione core (DKP, 33), shown in Figure 2.1. 
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33 
Figure 2.1: General structure of 1,4-disubstituted diketopiperazine 2,5-dione (33). 
 
2.2-  Introduction 
 
Diketopiperazines, the smallest cyclic peptides known, are very important in biology 
and drug discovery as it is possible to obtain amino acids from them, rendering them 
a possible substitute for common peptides.  DKPs can be used to stereoselectively 
incorporate  an  amino  acid  functionality  into  a  molecule  and  be  selectively 
deprotected under mild condition using cerium ammonium nitrate (CAN).
[1-3] 
These compounds have been found in both microorganisms
[4] and plants.
[5]  Like 
many products of microbial secondary metabolism they show antimicrobial activity 
against some organisms
[6,7] and in nature they are usually synthesised from a small 
library of primary metabolites. 
In nature there are three DKP isomers, 2,5 DKP (33), 3,5 DKP (41) and 5,6 DKP 
(42) with the most prevalent being 2,5-DKP , Figure 2.2.
[8,5,9]  2,5-DKP are also an 
unwanted side products in the synthesis of oligopeptides.
[10,11,12] 25 
 
 
RN
NR
O
O    
RN
NR
O
O
  
RN
NR
O
O
 
        33              41         42 
Figure 2.2: Three structural DKP isomers, 2,5 DKP (33), 3,5-DKP (41) and 5,6-DKP (42). 
 
DKPs  can  generate  amino  acids  or  peptides  through  hydrolysis  in  appropriated 
conditions, Figure 2.3.
[13,1] 
They are also important building blocks for other chiral compounds and they have 
potential  applications  in  industry  and  medicine.
[14,15,1]  Research  in  this  area  is 
ongoing.
[3,16]  For  instance  Pèrez-Picaso  et  al.  recently  reported  an  efficient 
microwave assisted synthesis using a one-pot cyclisation of Na-Boc-dipeptidyl tert-
buthyl esters (43)
[17] and Sollis et al. describing the multicomponent Ugi reaction to 
synthesize trisubstituted DKPs (44), Figure 2.3.
[18] 
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      43          44 
Figure 2.3: Example of Nα-Boc-dipeptidyl ester (43) and example of chiral trisubstituted 2,5-
diketopiperazine (44). 
 
The  synthesis  of  the  1,4  disubstituted  DKP  template  has  also  been  used  in  the 
synthesis of 2,6-diaminopimelic acid (45) and derivatives of this amino acid (46, 47), 
shown  in  Figure  2.4,    as  well  as  in  the  synthesis  of  several  non-natural  amino 
acids.
[19-21]  
 26 
 
48  50 
HOOC COOH
NH2 NH2  
HOOC
NH2
COOH
NH2
 
      45          46     
COOH HOOC
NH2 H2N
 
47 
Figure 2.4: Structure of (2R, 6R) diaminopimelic acid (45); (2R, 7R) diaminosuberic acid (46) 
and(S,S) ortho-phenylene-bis-alanine (47) . 
 
The synthesis of DKP is widely described in literature and is usually reported as a 
four-steps  “head  to  tail”  synthesis,  in  which  the  first  step  is  the  Shotten-Baum 
reaction between phenylethyl amine (48) and chloroacetyl chloride (49) as shown in 
Scheme  2.1.  The  substitution  of  the  other  chlorine  with  a  second  molecule  of 
phenylethyl amine is followed by the attack of the amine to a second molecule of 
chloroacetyl chloride. The cyclisation is complete when the amide nitrogen attacks 
the electropositive carbon in a to the carbonyl substituting the chlorine in the same 
position. 
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Reagents and conditions: i) Na2CO3, Acetone/H2O; ii) Phenylethyl amine, K2CO3, EtOH; iii) 
chloroacetyl chloride, Na2CO3, Acetone/H2O; iv) n-BuLi, THF, 0 °C. 
Scheme 2.1: “Head to tail” four steps DKP (33) synthesis. 
 
In Paradisi’s laboratory DKP is the main scaffold used to synthesize amino acids, as 
shown in  Scheme 2.2.
[3] This alternate synthetic strategy involves the acylation of 
the commercially available amine (54) using chloro acetylchloride (49) leading to the 
chloroacetamide (55) followed by the cyclisation of the latest to achieve the final 
DKP (33). 28 
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Reagents and conditions: i) DCM, TEA, -10 °C-r.t. 2 h; ii) TEBA (10 mol %), NaOH, DCM, r.t., 48 h. 
Scheme 2.2: Synthesis of DKP (33) used in Paradisi’s laboratory. 
 
 
2.3-  Synthetic approach and discussion 
 
The first step in the synthesis of substituted benzyl DKP (56) is the preparation of 
chloroacetamide (55) via the Schotten-Baumann reaction, the acylation of the amine 
with the carboxylic acid chloride, as shown in Scheme 2.3.  During the course of the 
reaction one molecule of hydrochloric acid is produced and so one equivalent of base 
is  used  to  neutralise  it  and  to  avoid  the  formation  of  the  amine  salt  driving  the 
equilibrium. The reaction is very effective and proceeds with high yields. The crude 
product of the reaction seems quite clean, even without purification, but it has been 
noticed that after silica gel chromatography column the yield of the successive step 
in this sequence, namely the cyclisation with TEBA is higher.  
  
54 
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 54(a, b)      49          55 
a R = H; R1 =  H 
b R = CH3; R1 =  OCH3 
Reagents and conditions: i) DCM, TEA, -10 °C-r.t., 2 h. 
 Scheme 2.3: Acylation of the amine (54) chloroacetamide (55)  
 
The problem with bifunctional molecules such as chloroacetamides is their tendency 
to polymerise under certain conditions, in fact they are often isolated as side products 
of peptide synthesis.
19,20 Usually high concentrations favour polymerisation and high 
dilutions favour cyclisation.
21  Reaction described in Scheme 2.4 seem to be totally 
selective towards the cyclisation. 
The  product  (55)  is  recognisable  from  the 
1H-NMR  spectrum  (for  instance  for 
compound  55a,  Figure  2.5  )  because  of  the  characteristic  peaks  of  the  benzylic 
protons at 7.39 and 7.26 ppm, of the nitrogen 6.86 ppm, of the benzylic methylene at 
4.50 ppm and of the methylene in a to the carbonyl at 4.11 ppm.  
 
Figure 2.5: 
1H-NMR in CDCl3 of the benzyl-acetamide (55a). 
 30 
 
The cyclisation of chloroacetamide (55) shown in Scheme 2.4, was performed in the 
presence of a phase transfer catalyst (PTC) to produce DKPs (56) in very high yields 
(70-90 %).
[3] 
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      55              56 
a R = H; R1 =  H 
b R = CH3; R1 =  OCH3 
Reagents and conditions: i) DCM, acryloyl chloride, TEBA (10 mol %), r.t., 48 h. 
 Scheme 2.4: Cyclisation of the amide (55a,b).  
 
PTCs increase the rate of the reaction under mild conditions.  The PTC employed in 
this reaction was benzyltriethylammonium chloride (TEBA).  As it is soluble in both 
aqueous and organic phases it allows the interaction between the two phases in a 
heterogeneous  system.    Hydroxide  ions  (OH
-),  the  reactive  anion  of  sodium 
hydroxide (NaOH), the inorganic base, are continuously introduced into the organic 
phase in the form of lipophilic ion pairs, where the lipophilic cations are supplied by 
the  catalyst.
[25,26]    The  concentration  of  the  reacting  anions  in  the  organic  phase 
cannot exceed the concentration of the catalyst (10 mol %).  The catalyst (57) forms 
a partial covalent bond with the hydroxyl ion of the base, forming the active catalyst 
(58) which, once in the organic phase, can deprotect the amide nitrogen (59) which 
nucleophilically  attacks  the  carbon  in  a  to  another  molecule  of  chloroacetamide 
forming compound (60).  The second deprotonation of the nitrogen (compound 61) 
and nucleophylic attack produce the DKP (33) as shown in Scheme 2.5. 
 31 
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Scheme 2.5: Phase transfer catalysed DKP (33) synthesis. 
 
The 
1H-NMR  spectrum  of  compound  (56a,  Figure  2.6)  shows  the  characteristics 
peaks of the benzylic protons at 7.26-7.35, the singlet of the benzylic methylene is 
now shifted to 4.6 ppm respect the previous spectrum and the one of the methylene 
in  a  to  the  carbonyl  is  now  shifted  to  1.6  ppm.  In  the  case  of  the  para-
methoxybenzyl-diketopiperazine there is also the peak of the methoxy group at 3.9 
ppm 
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Figure 2.6: 
1H-NMR in CDCl3 of the DKP (56a). 
 
Further investigations have lead to the development of a new procedure for the one-
pot synthesis of substituted benzyl DKP (56), in which the PTC (57) is added to the 
reaction from the beginning with NaOH as base, avoiding the use of TEA, as shown 
in Scheme 2.6.
[27]  Chloroacetamides can be easily prepared from the corresponding 
amine, as shown in Scheme 2.2, but they need purification before the cyclisation 
step, which lengthens the overall synthetic process and inevitably affects the overall 
yield.  The original method has been extended to incorporate the synthesis of the 
chloroacetamide and its selective cyclisation in one-pot under PT conditions. 
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    54                   56 
a R = H; R1 =  H 
b R = CH3; R1 =  OCH3 
c R = CH3; R1 =  H 
Reagents and conditions: i) C2H2Cl2O, DCM, NaOH (50 %),TEBA (10 mol %) 48 h. 
Scheme 2.6: Phase transfer catalysed one-pot DKP synthesis (56). 
 
2.4-  Conclusions 33 
 
 
As  already  mentioned,  DKPs  (33)  are  important  in  numerous  research  fields, 
especially for their capability to generate amino acids.  
In this research project a one-pot synthesis of 1,4-disubstituted piperazine-2,5-dione 
(33) has been developed employing a PTC (57), starting from a suitable amine and 
chloroacetyl chloride (49). 
The development a one-pot procedure for the synthesis of organic compound is an 
important achievement. It allows the desired product to be obtained in a shorter time 
period and without expensive purification which is usually required in a step-by-step 
synthesis. In this specific case, the one-pot procedure avoids the purification of the 
on a silica gel chromatography column, because the DKP core (33) is reached in only 
one  step  using  PTC  (57)  and  with    a  reaction  selectivity  towards  the  cyclisation 
rather than the polymerisation of chloroacetamide (55). 
With this easy procedure, starting from different commercially available amines (54), 
it is possible to obtain different typology of 1,4-disubstituted piperazine-2,5-dione 
(56), which can be hydrolysed to the corresponding amino acid. Amino acids, both 
natural and non natural, are useful building blocks for numerous biological active 
molecules  and  in  the  case  of  this  research  project  the  goal  is  the  synthesis  of  a 
molecule with potentially antimicrobial activity, (S)-2-ammonio-3-((1R,6R)-2-oxo-7-
oxa-3-aza-bicyclo[4.1.0]heptan-5-yl)propanoate (25). 
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2.5-  Experimental section 
 
-  N-benzyl-2-chloroacetamide (55a)
[3] 
 
HN
O
Cl
 
 
To a stirred solution of benzyl amine (54a, 1 g, 9.3 mmol) and triethylamin (TEA, 
1.41  g,  13.6  mmol)  in  dichloromethane  (DCM,  15  mL)  at  -10  °C  was  added 
chloroacetyl chloride (49, 1,26 g, 11.2 mmol) dropwise.  The solution was allowed to 
reach room temperature and after 2 hours was cooled to 0 °C before water (10 mL) 
and 10 % HCl until neutralisation were added.  The organic phase was removed in 
vacuo after extracting the aqueous phase with EtOAc (3 x 15 mL).  The combined 
organic layers were dried over MgSO4 and concentrated in vacuo to produce a crude 
brown  solid  that  was  purified  by  silica  gel  chromatography  column 
(EtOAc:Cyclohexane,  50:50)  to  produce  a  white  solid  in  76  %  yield.  Rf:  0.8, 
Cyclohexane:EtOAc, 50:50; δH (400 MHz; CDCl3): 7.39-7.26 (m, 5H, Ph), 6.86 (br. 
s,  1H,  NH),  4.51-4.49  (d,  J  =  5.8,  2H,  CH2Ph),  4.11  
(s, 2H, CH2Cl); 166.00 (CO), 137.47 (Ph), 129.23 (Ph), 127.94 (Ph), 44.45 (CH2N), 
43.09 (CH2Cl). 
 
-  (S)-2-Chloro-N-(1-(4-methoxyphenyl)ethyl)acetamide (55b)
[3] 
 
H3CO
N
H
Cl
O CH3
 
 
To a stirred solution of (S) 1-(4-methoxyphenyl)ethanamine (54b, 0.7 g, 4.6 mmol) 
and triethylamin (TEA, 0.97 mL, 6.9 mmol) in dichloromethane (DCM, 20 mL) at -
10 °C was added chloroacetyl chloride (49, 0.45 mL, 5.6 mmol) dropwise.  The 
solution was allowed to reach room temperature and after 2 hours was cooled to 0 °C 35 
 
before water (10 mL) and 10 % HCl until neutralization were added.  The aqueous 
phase was washed with EtOAc (3 x 15 mL), the organic layers were combined, dried 
over MgSO4 and concentrated in vacuo to produce a crude brown solid that was 
purified  by  silica  gel  chromatography  column  (EtOAc:Cyclohexane,  50:50) 
obtaining a white solid in 76 % yield:. Rf: 0.63, Cyclohexane:EtOAc, 50:50; dH (600 
MHz, CDCl3) 7.29–7.24 (d, J = 6.8 Hz, 2H, Ph), 6.90–6.88 (d, J = 8.7, 2H, Ph), 6.73 
(br. s, 1H, NH), 5.14-5.05 (m, 1H, CH), 4.05-3.99 (d, J = 7.1 Hz, 2H, CH2), 3.80 (s, 
3H, OCH3), 1.53-1.51 (d, J = 6.9 Hz, 3H, CH3CH); dC (151 MHz, CDCl3) 164.80 
(CO),  159.06  (Ph),  134.42  (Ph),  127.31  (Ph),  114.15  (Ph),  55.29  (CH2Cl),  48.70 
(CH3O),  42.63  (CH),  21.51  (CH3CH);  50:50;  HRMS  (EI):  m/z  calcd  for 
C11H14ClNO2: 227.0713, found: 227.0711; [a]
20
D – 89 (c 0.35, CHCl3); mp: 243–245 
°C. 
 
-  1,4-dibenzylpiperazine-2,5-dione (56a)[3],
[27] 
 
N
O
N
O  
 
To a stirring solution of 2-chloro-N-(benzyl)acetamide (55a, 1.61 g, 7.0 mmol) in 
DCM (20 mL) were added NaOH 50% (4.5 mL) and TEBA over time (10 % mol). 
The reaction was left for 48 hours, cooled down to 0 °C and water (20 mL) and HCl 
until neutralization were added. The aqueous phase was washed with DCM (3 x 20 
mL),  the  organic  phases  were  combined,  dried  with  MgSo4  and  concentrated  in 
vacuo.  The  product  was  purified  via  silica  gel  chromatographic  column 
(EtOAc:cyclohexane from 15:85 to 60:40) in 85 % yield as a white solid.  
Alternate strategy consists in starting from a stirring solution of benzyl amine (54a, 
0.51 mL, 4.66 mmol) in DCM (8 mL). NaOH 50% (3 mL, 37.3 mmol) and drop-wise 
chloroacetyl chloride (0.45 mL, 5.6 mmol) were added, after cooling the temperature 
to  -10  °C.  The  solution  was  allowed  to  warm  slowly  to  room  temperature.  The 
formation  of  the  amide  was  monitored  by  TLC  and  once  the  amine  had  been 
consumed, TEBA (10 % mol) was added gradually over 48 hours to the vigorous 36 
 
stirred solution. The reaction was quenched firstly with water  (20 mL) and then 
brought to pH 7 by the addition of 10 % HCl at 0 °C. The DCM was removed in 
vacuo, the aqueous phase was washed with EtOAc (3 x 20 mL), the organic phases 
were  combined,  dried  with  MgSo4  and  concentrated  in  vacuo.  The  product  was 
purified via silica gel chromatographic column (EtOAc:cyclohexane from 20:80 to 
60:40) in 90 % yield as a white solid. Rf: 0.39, Cyclohexane:EtOAc, 50:50; dH (300 
MHz, CDCl3) 7.38-7.23 (m, 10 H, Ph), 4.58 (s, 4H, CH2Ph), 3.93 (s, 4H, CH2N); dC 
(75 MHz, CDCl3) 163.2 (CO), 134.9 (Ph), 128.9 (Ph), 128.5 (Ph), 128.2 (Ph), 49.3 
(CH2N), 49.2 (CH2Ph); mp: 175–176 °C; Anal.Calcd for C18H18N2O2: C, 73.45; H, 
6.16; N, 9.52. Found: C, 73.38; H, 6.27; N, 9.43. 
 
-  1,4-Bis[(S)-1-(4-methoxyphenyl)ethyl]piperazine-2,5-dione (56b)
[3] 
 
N
O
N
O
OCH3
CH3
CH3
H3CO
 
 
To a stirring solution of (S)-2-Chloro-N-(1-(4-methoxyphenyl)ethyl)acetamide (55b, 
1.45 g, 6.4 mmol) in DCM (10 mL) were added NaOH 50% (4.0 mL) and TEBA 
over time (10 % mol). The reaction was left for 48 hours, cooled down to 0 °C and 
water (20 mL) and HCl until neutralization were added. The aqueous phase was 
washed  with  DCM  (3  x  20  mL),  the  organic  phases  were  combined,  dried  with 
MgSo4  and  concentrated  in  vacuo.  The  product  was  purified  via  silica  gel 
chromatographic column (EtOAc:cyclohexane from 15:85 to 60:40) in 40 % yield as 
a white solid.  
Rf: 0.18, Cyclohexane:EtOAc, 50:50; δH (500 MHz; CDCl3): 7.20–7.15 (m, 4H, Ph), 
6.89–6.82 (m, 4H, Ph), 5.88 (q, J = 7.1 Hz, 2H, CH), 3.81 (d, J = 16.5 Hz, 2H, 
CH2N), 3.78 (s, 6H, CH3O), 3.49 (d, J = 16.5 Hz, 2H, CH2N), 1.50 (d, J = 7.2 Hz, 
6H, CH3CH); δH (126 MHz, CDCl3) 163.67 (CO), 159.25 (Ph), 130.19 (Ph), 128.52 
(Ph), 114.05 (Ph), 55.20 (CH2N), 49.61 (CH), 44.45 (CH3CH), 15.21 (CH3O); Anal. 37 
 
Calcd for C22H26N2O4: C, 69.09; H, 6.85; N, 7.32. Found: C, 68.95; H, 6.93; N, 7.13. 
a
20
D - 383.5 (c 0.65, CHCl3); mp: 98–99 °C. 
 
-  1,4-Bis[(S)-1-phenylethyl]piperazine-2,5-dione (56c)
[27] 
 
 
N
CH3
N
O
O CH3  
 
To a stirring solution of (S)-phenylethyl amine (54c, 1 mL, 7.86 mmol) in DCM (15 
mL)  were  added  NaOH  50%  (5.3  mL),  chloroacetyl  chloride  (49,  0.75  mL,  9.4 
mmol) dropwise, after cooling the temperature to -10 °C. The solution was allowed 
to warm slowly to room temperature. The formation of the amide was monitored by 
TLC  and  once  the  amine  had  been  consumed,  TEBA  (10  %  mol)  was  added 
gradually over 48 hours to the vigorous stirred solution. The reaction was quenched 
firstly with water (20 mL) and then brought to pH 7 by the addition of 10 % HCl at 0 
°C. The DCM was removed in vacuo, the aqueous phase was washed with EtOAc (3 
x 20 mL), the organic phases were combined, dried with MgSo4 and concentrated in 
vacuo.  The  product  was  purified  via  silica  gel  chromatographic  column 
(EtOAc:cyclohexane from 20:80 to 60:40) in 40 % yield as a white solid. Rf: 0.15; 
dH (500 MHz, CDCl3) 7.56-7.16 (m, 10 H, Ph), 5.95 (q, 2H, J = 7.1 Hz, CH), 3.86 (d, 
2H, J = 16.7 Hz, CH2), 3.52 (d, 2H, J = 16.7 Hz, CH2), 1.54 (d, J = 7.1 Hz, 6H); dC 
(126 MHz, CDCl3) 163.8 (CO), 138.3 (Ph), 128.8 (Ph), 128.1 (Ph), 127.3 (Ph), 50.1 
(CH2N),  44.7  (CH);  15.1  (CH3);  mp:  108–110  °C;  HRMS  (EI):  m/z  calcd  for 
C20H22N2O2: 322.1681, found: 322.1693; [a]
20
D – 319.1 (c 2.2, CHCl3). 38 
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3.1-  Aim  
 
The aim of this second part of the project is to synthesise the side chain of the (S)-2-
ammonio-3-((1R,6R)-2-oxo-7-oxa-3-aza-bicyclo[4.1.0]heptan-5-yl)propanoate (25). 
 
HN
O
O
COO
NH3
 
25 
Figure 3.1: (S)-2-ammonio-3-((1R,6R)-2-oxo-7-oxa-3-aza-bicyclo[4.1.0]heptan-5-
yl)propanoate (25). 
 
 
3.2-  Introduction 
 
This side chain of our target analogue (25) was chosen in order to render the attack 
on  the  carbonyl  carbon  and  the  hydrolysis  to  form  hydrate  (24)  less  likely,  as 
explained in the Section 1.4. Methyl amine (62) and methyl propiolate (40) were 
chosen  as  starting  materials  as  they  are  commercially  available  and  enabled  the 
synthesis of a six-member ring with an amide functionality (d-lactame like). Many 
pharmaceuticals contain a nitrogen atom, it was postulated that the introduction of a 
nitrogen  into  this  six-member  ring  would  potentially  lead  to  interesting  novel 
activity. 
The  reaction  pathway  initially  attempted  involved  6  steps,  as  shown  below  in 
Scheme 3.1. 
This synthetic strategy involves the conjugate addition of the commercially available 
methyl amine (62) to methyl propiolate (40) to produce compound (63).  This was 
followed by an aza-anulation with acryloyl chloride (38) to product the δ-lactone 
(64). Reduction of the heterocyclic olefin leads to the production of compound (65) 
which was then further reduced to the corresponding alcohol (66). The next step 41 
 
involved the substitution of the alcoholic moiety with the iodine one, leading to the 
compound (68) passing through the mesylated compound (67). 
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Scheme 3.1: Pathway for the synthesis of 5-(iodomethyl)-1-methylpiperidin-2-one (68). 
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3.3-  Synthetic approach and discussion 
 
The  first  step  of  the  synthetic  route  was  the  formation  of  the  (E)-methyl  3-
(methylamino)acrylate (63) obtained by the conjugate addition of methylamine (62) 
to methyl propiolate (40). This reaction gave a mixture of diasteroisomers in a ratio 
of approximately 70:30 (Scheme 3.2), with a yield of 75 %. At this point it was not 
possible to accurately determine which diasteroisomer had been formed in majority, 
however the specifics of the ratio are discussed below. The methyl amine (62) is very 
volatile, with a boiling point of -6 °C, so the reaction is performed at -10 °C. The 
reaction was carried out under nitrogen to avoid the preferential addition of water to 
the triple bond. 
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          62        40        63 
Reagents and conditions: i) THF, -10 °C, 2 h. 
 Scheme 3.2: Conjugate addition of methyl amine (62) to methyl propiolate (40) to obtain enamine 
(63)  
 
The proposed mechanism of this reaction is shown below, Scheme 3.3: The lone pair 
of  the  amine  (62)  attacks  the  triple  bond  of  methyl  propiolate  (40)  and  after 
rearrangement to a diene intermediate (69), this leads to the formation of the two 
diesteroisomers of enamine [E-(63)] and [Z-(63)]. 43 
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     62       40      69        E-63    Z-63 
Scheme 3.3. Mechanism of the reaction of  methyl amine (62) and methyl propiolate (40), via diene 
(69) producing enamine [E-(63)] and [Z-(63)]. 
 
The  product  of  this  reaction  (63)  degrades  on  silica  gel  but  the  conversion  is 
quantitative as shown by the 
1H-NMR spectrum of the crude and no purification is 
required (Figure 3.2).  The spectrum shows the olefinic protons as a quartet for those a 
to the nitrogen at approximately 7.55 ppm and 6.59 ppm for diastereoisomers a and b 
respectively.  The other alkene protons in the position a to the carbonyl carbon are shown as 
a doublet of doublets at approximately 4.74 ppm and 4.49 ppm for diastereoisomers a and b 
respectively.  The recognisable broad peak of the amine group occurs at 4.55 ppm. The 
characteristic singlets of the methoxy protons are visable at 3.67 ppm (diastereoisomer a) 
and  3.64  ppm  (diastereoisomer  b),  with  a  doublet  for  the  methyl  group  bonded  to  the 
nitrogen, at around 2.97 ppm (diastereoisomer b) and 2.78 ppm (diastereoisomer a).  
 
 
Figure 3.2: 
1H-NMR in CDCl3 f the enamine (63). 
The creation of the methyl 1-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate 
(64)  proceeds  via  an  aza-annulation  reaction  of  the  enamine  (63)  and  acryloyl 44 
 
chloride (38),
[1,2] as shown in Scheme 3.4. The presence of the electron withdrawing 
ketone and ester functionalities enhance significantly the efficiency and selectivity of 
the annulations.
[1] 
The overall yield of this reaction was relatively low, 47 %.  This was possibly due to 
only one of the two diasteroisomers reacting; sterics dictate that the cis isomer (Z-63) 
is more likely to cyclise than the trans isomer (E-63).  From this speculation it was 
postulated  that  it  was  the  cis  siomer  (Z-63)  that  had  been  synthesised  in 
approximately 70% previously (Schemes 3.2 and 3.3, Figure 3.2)  Furthermore, TLC 
evaluation of the reaction showed several side products, denoted by the visualisation 
of many different spots meaning that the reaction was not very clean.  To avoid the 
addition of water to the double bond of enamine (63) and its nucleophilic attack on 
the carbonyl functionality of the acryloyl chloride (38), the reaction was performed 
under nitrogen.  
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        63                64 
Reagents and conditions: i) THF, CH2CHCOCl, reflux, 2 h. 
Scheme 3.4: Aza-annulation reaction between enamine (63) and acryloyl chloride (38). 
 
The mechanism of the aza-annulation reaction has not been fully elucidated but a 
proposed mechanism is shown below (Scheme 3.5).  Initially, the double bond of the 
enamine  (63)  attacks  the  alkene  functionality  of  acryloyl  chloride  (38),  which 
consequently rearranges to give the form (70) and then (71). The chlorine is a good 
leaving group and the lone pair of the nitrogen easily attacks the carbonylic carbon 
generating the etherocycle (72). The last rearrangement of (71) allows the formation 
of (64). 
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Scheme 3.5: Mechanism of aza-annulation. 
 
The spectrum shows the distinctive singlet of the olefinic proton at 7.27 ppm, in part 
hidden by the peak of chloroform.  The singlet of the methoxy group is observed at 
3.75 ppm, with the singlet of the methyl group, bonded to the nitrogen, at 3.15 ppm.  
The four aliphatic protons of the heterocycle appear as a multiplet at 2.61 ppm, as 
shown in Figure 3.3. 
63  38 
71 
72  64 46 
 
 
Figure 3.3: 
1H-NMR in CDCl3 of the product of the aza-annulation( 64). 
 
Compound (64) was then reduced via palladium catalysed hydrogenation to produce 
the  racemic  methyl  1-methyl-6-oxopiperidine-3-carboxylate  (65),  as  shown  in 
Scheme 3.6, in 85 % yield.  This reaction has to be performed very carefully under 
strictly anhydrous conditions as both hydrogen  and palladium can react violently 
with water.  This reduction was first attempted using NaBH4 (and then LiBH4) as 
reducing agents.  This was performed in an endeavour to simultaneously reduce the 
double bond of the heterocycle and of the ester function, to produce compound (65).  
Neither  of  these  hydrides  was  strong  enough  to  reduce  the  double  bond,  so  this 
methodology  was  not  further  pursued  and  the  reduction  was  carried  out  in  two 
separate steps. 47 
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         64              65 
Reagents and conditions: i) EtOH, H2, Pc/C, r.t., 12 h. 
Scheme 3.6: Hydrogenation of compound (64) to give compound  
(65). 
 
The 
1H-NMR spectrum of compound (65) is now much more complicated than the 
starting material of the reaction, compound (64).  The reduction of the olefin means 
that the heterocycle looses the planar characteristics associated with sp
2 hybridised 
carbons.  The interactions of axial and equatorial protons round the flexible ring 
mean that all the signals, apart from the methyl and methoxy group (singlets), are 
multiplets (Figure 3.4).  
 
 
Figure 3.4: 
1H-NMR in CDCl3 of the product of the hydrogenation (65). 
 
For  an  easy  identification  of  the  signals,  numbers  have  been  assigned  to  the 
heterocycle atoms (73), as shown in Figure 3.5. Starting from the lower frequencies 
we find two multiplets relative to the CH2 5, two multiplets of the methylene 6, a 48 
 
multiplet of the proton 4 and around 3.5 ppm the multiplets of the protons 3 (less 
shielded because next to the nitrogen)  
As expected, the peak of the alkene proton is not present anymore.  
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Figure 3.5: Compound (65) in which heterocycle atoms have been assigned numbers for ease of 
identification. 
 
Lactame (65) was then reduced further.  LiBH4 was used to reduce the ester function 
to  5-(hydroxymethyl)-1-methylpiperidin-2-one  (66)  in  60  %  yield,  as  shown  in 
Scheme 3.7.  Again the reaction was carried on under nitrogen flow, because hydride 
reacts violently with water. 
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          65               66 
Reagents and conditions: i) THF,LiBH4, 0 °C-r.t., 12 h. 
Scheme 3.7: Reduction of the ester function to alcohol (66). 
 
Comparing the spectrum of this purified alcohol (66), Figure 3.6, to that of the ester 
(65), figure 3.4, it is observed that the signal of the methoxy group (3.6 ppm) is no 
longer present.  Additionally the generation of CH2OH in place of the ester has led to 
the creation of new multiplets at approximately 3.3 and 3.4 ppm.  The large peak at 
3.4 is due to residual methanol in the sample.   
 49 
 
 
Figure 3.6: 
1H-NMR in CD3OD of the alcohol (66) . 
 
The next step in the proposed synthesis was the exchange of the alcohol functionality 
in (66) with iodine to create compound (68, Scheme 3.8).  The alcohol functionality 
is not exchanged directly with iodine, but the reaction proceeds via the mesylate 
intermediate (67).  The reactions are performed in this way as mesylate is a better 
leaving group than the hydroxyl and it activates the alcohol (66) thus increasing the 
final yield of compound (68).  Mesylation is usually carried out with TEA in DCM.  
In this instance compound (66) was insoluble in DCM so pyridine was used as both 
base and solvent for the reaction leading to 80 % yield.  Mesyl chloride reacts readily 
with water, producing the methanesulfonic acid; therefore the reaction is performed 
under anhydrous conditions. 
The  mesylate  compound  (67)  did  not  require  purification  before  iodination  to 
produce 5-(iodomethyl)-1-methylpiperidin-2-one (68) in 83 % yield.    
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Reagents and conditions: i) Py,CH3ClO2S, 0 °C- refluz,2 h; ii) acetone, NaI, reflux, 5 h. 50 
 
Scheme 3.8: Exchange of the alcohol (66) with the iodide (68). 
 
The 
1H-NMR spectrum of compound (68, Figure 3.7) does not differ significantly 
from  the  alcohol  spectrum  (66),  Figure  3.6,  but  the  peaks  are  slightly  shifted  to 
higher  frequencies,  due  to  a  difference  in  the  electronegativity  of  the  iodine 
compared to the alcoholic moiety  
 
 
Figure. 3.7: 
1H-NMRin CD3OD of the iodo-compound (68) . 
 
At  this  stage  the  side  chain  (68)  was  ready  to  be  coupled  with  the  previously 
prepared substituted benzyl diketopiperazine core (56), as shown in Scheme 1.7 in 
Section  1.4,  however  this  coupling,  with  LHMDS,  was  unsuccessfully  and  only 
starting  materials  and  a  complex  mixture  of  side-products  were  isolated.    This 
unsuccessful  coupling  was  unexpected  as  similar  reactions  had  been  performed 
successfully many times using several different alkylating agents including methyl 
iodide (74), ethyl iodide (75) and benzyl iodine (76), Figure 3.8. 
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Figure 3.8: Alkilating agents. 51 
 
 
When investigating the possible reasons for this unsuccessful coupling, the reaction 
of the iodo-compound (68) and LHMDS was examined, as shown in Scheme 3.9.  
After purification by silica gel column chromatography compound (77) was isolated, 
derived from an intramolecular cyclisation and elimination of iodine.   
The isolation of this compound (77) from the reaction is not entirely surprising as the 
protons in the a position to the carbonyl carbon are very acidic and the iodine is very 
reactive. However, the strain of a four-member ring fused to a six-member ring was 
thought  to  be  unfavoured.  Interestingly,  this  product  was  not  isolated  during  the 
coupling with the diketopierazine moiety.  
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         68        77 
Reagents and conditions: i) THF, LHMDS,. 
Scheme 3.9: Reaction of (68) in presence of the only base. 
 
It is possible that the problems observed during the coupling are due to the fact that 
the enolate on the diketopiperazine (78) is quenched by the formation of a second 
enolate on the alkylating group (79), as shown in Figure 3.9 and as will be discussed 
more in detail in chapter 4. 
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                 78          79 
Figure 3.9: Competitive enolate forms in the reaction of coupling between compound (68) and DKP 
(33). 52 
 
 
If this happens faster than the alkylation reaction, no product is isolated. At this 
stage, after the unsuccessful coupling it was decided to investigate a new synthetic 8 
step strategy, as shown below in Scheme 3.10.   
By protecting the nitrogen with an easily removable para-methoxy benzyl group, 
instead  of  the  methyl  group,  it  was  envisaged  that  the  amide  carbon  could  be 
protected as lactim (87) thus making the protons of the α position significantly less 
reactive, shown in Scheme 3.10.  
This  synthetic  strategy  up  to  the  formation  of  the  iodinated  compound  (85)  is 
identical  to  what  previously  reported  in  Scheme  3.1.  It  involves  the  conjugate 
addition  of  the  commercially  available  methoxyphenyl  amine  (39)  to  methyl 
propiolate (40) to produce the enamine form (80) followed by an aza-anulation with 
acroyl chloride (38) to produce the heterocycle (81). Reduction of the heterocyclic 
olefin leads to compound (82) which was then further reduced to the relative alcohol 
(83). The next step involved the substitution of the alcoholic moiety with the iodide, 
leading to the compound (85) passing through the mesylated compound (84). The 
iodo-compound  (85)  was  deprotected  at  the  amide  nitrogen  (86)  using  cerium 
ammonium nitrate (CAN) to allow in the next step the protection of the carbonyl 
(87). 
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Scheme 3.10: Alternative pathway for the synthesis of the lateral chain (87). 
 
The first step of this new synthetic route is again a conjugate addition, this time 
between the more hindered amine, methoxyphenyl amine (39), and methyl propiolate 
(40).   
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  40      39            80 
Reagents and conditions: i) THF, -10 °C, 2h. 
Scheme 3.11: Reaction of formation of the enamine (79) through conjugate addition. 
 
In  the 
1H-NMR  spectrum  (Figure  3.10)  again  are  visible  the  peaks  of  both  the 
diasteroisomers of methyl 3-(4-methoxybenzylamino)acrylate, [E-(80)] and [Z-(80)], 
formed  by  the  reaction  (ratio  E:Z  is  again  approximately  70:30).    This  reaction 
proceeds  very  well,  with  99  %  yield  and  does  not  require  purification.    In  the 
spectrum the characteristic protons of the phenyl appear at approximately 7 ppm, 
split in two groups because of the para-methoxy group that shields the two protons 
that are in the ortho position relative to the methoxy group. At 7.6 ppm and 6.8 ppm 
we can see the peaks of the protons of the double bond closer to the carbonyl carbon 
(cis and trans), with the alkene protons closer to the nitrogen occurring as doublets at 
4.8 ppm (trans) and 4.6 ppm (cis).  The methylene protons of the benzyl group are 
observed at 4.4 ppm and 4.2 ppm. Finally the characteristic singlets of the methoxy 
groups appear at 3.9 ppm and 3.7 ppm., for the methoxy moieties of the benzylic and 
ester groups respectively.   55 
 
 
Figure 3.10: 
1H-NMR in CDCl3 of the enamine (80). 
 
Methyl  1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate  (81) 
was produced by a reaction between enamine (80) and acryloyl chloride (38), as 
shown in Scheme 3.12.  
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      80              81 
Reagents and conditions: i) THF, CH2CHCOCl, r.t., 12h. 
Scheme 3.12 Aza-annulation reaction. 
 
The reaction between enamine (80) and acryloyl chloride (38) is not as clean as that 
previously described for enamine (63). The six-membered ring d-lactam-like (81) is 
isolated in only 33 % yield.  Several side products were observed by TLC and again 
it is suggested that only one of the two isomers, the cis, was reactive.  The 
1H-NMR 
spectrum, Figure 3.11, shows the distinctive signal of the alkene proton at 7.3 ppm, 
as a singlet, with the two groups of the phenyl protons at approximately 7.3 ppm.  56 
 
The singlet of the protons of the benzylic methylene group is observed at 4.7 ppm.  
The singlets of the methoxy groups, respectively for the one bonded to the phenyl 
ring  and  for  that  which  forms  the  ester  group  are  at  3.9  ppm  and  3.7  ppm 
respectively.    Finally  at  2.6  ppm  the  signal  of  the  four  aliphatic  protons  of  the 
heterocycle can be recognised.  
 
 
Figure 3.11: 
1H-NMR in CDCl3 of the six-membered ring with (81). 
 
The double bond of the six-membered ring delta lactam like (81) was then reduced 
via palladium catalysed hydrogenation to produce methyl 1-(4-methoxybenzyl)-6-
oxopiperidine-3-carboxylate (82), as shown in Scheme 3.13, with a yield of 86 %. 
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      81              82 
Reagents and conditions: i) EtOH,, H2, Pd/C,r.t., 12h. 
Scheme 3.13: Hydrogenation of compound (80) to give compound (81). 
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The 
1H-NMR  spectrum  for  methyl  1-(4-methoxybenzyl)-6-oxopiperidine-3-
carboxylate (82) again had become more complicated than the starting material of 
this  reaction  (81)  as  the  reduction  of  the  olefin  has  decreased  the  planar 
characteristics of the molecule and the axial and equatorial protons interact more 
producing more multiplets (signals between 2 and 4 ppm). This was a previously 
observed phenomenon, with compound (65), as shown in Figure 3.12. 
 
 
 
Figure 3.12: 
1H-NMR in CDCl3 of the six-membered ring without after reduction of the double bond 
(82). 
 
For  an  easy  identification  of  the  signals,  numbers  have  been  assigned  to  the 
heterocycle atoms (88), as shown in Figure 3.13. Starting from the lower frequencies 
we find two multiplets relative to the methylene 5, two multiplets of the protons 6, a 
multiplet of the proton 4 and around 3.4 ppm the multiplets of the protons 3, more 
shielded  because  closest  to  the  nitrogen.    Around  4.6  ppm  there  are  the  signal 
(doublet of doublet) of the benzylic CH2.  
The signal of the olephinic proton is no more visible. 
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Figure3.13: Compound (82) in which heterocycle atoms have been assigned numbers for ease of 
identification. 
 
The  ester  function  was  reduced  with  LiBH4  to  produce  5-(hydroxymethyl)-1-(4-
methoxybenzyl)piperidin-2-one  (83)  in  85  %  yield.  This  shows  a  significant 
improvement in yield compared to the reduction of compound (66) that was 60 % of 
yield. The reason of the improvement was probably due to the better solubility of 
compound (83).  
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N
O
O OCH3
H3CO
 
      82              83 
Reagents and conditions: i) THF, LiBH4, 0 °C-r.t., 16 h. 
Scheme 3.14: Reduction of the ester function (82) to alcohol (83). 
 
Several  differences  can  be  observed  when  comparing  this 
1H-NMR  spectrum  in 
Figure 3.14 with the previous one. The protons of the benzylic methylene (4.6 ppm) 
now appear as a singlet, whereas they previously occurred as a doublet of doublet.   
Furthermore the large singlet of the ester methoxy moiety of compound (82) has 
disappeared and in its place two new multiplets at approximately 4.6 ppm can be 
seen.  These are representative of the new methylene created by the reduced ester’s 
carbonyl carbon.   
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Figure 3.14: 
1H-NMR in CDCl3 of the alcohol (83). 
 
Before the exchange of the alcohol of compound (83) with the iodine, it was first 
activated by substituting with a better leaving group, namely mesylate to produce 
compound (84), as shown in Scheme 3.15. This reaction proceeded well, with 93 % 
yield,  better  than  that  of  the  previously  synthesised  compound  (67,  80  %).  The 
iodination of compound (85) was performed using sodium iodide in acetone.  Again 
this reaction gave a high yield (80 %), and the overall yield for these two steps was 
78 %. 
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    83        84          85 
Reagents and conditions: i) DCM, TEA, -10 °C-r.t., 16 h; ii) acetone, NaI, reflux, 4 h. 
Scheme 3.15: Exchange of the alcohol with the iodine. 
 
The 
1H-NMR  spectrum  of  compound  (85)  does  not  differ  significantly  from  the 
spectrum of the alcohol (83, Figure 3.14), as shown in Figure 3.15. 60 
 
 
 
Figure 3.15: 
1H-NMR in CDCl3 of the iodo-compound (85). 
 
Cerium  ammonium  nitrate  (CAN),  in  acetonitrile  and  water  (3:2),  was  used  to 
deprotect the amide functionality of compound (85) as a method by which to obtain 
(86), as shown in scheme 3.16. This is one of the most used reactions of deprotection 
for the methoxy-benzyl group. This reaction proceeded in 41 % yield. After 2 hours 
starting material was still present. It has been tried to leave the reaction over night in 
order to increase the yield, but the product decomposed. 
Because of its high oxidative ability, its good solubility in a wide number of organic 
solvents  and  its  low  toxicity,  CAN  is  largely  used  as  oxidative  reagent  also  to 
deprotect  ethers,
[3]  chemoselective  catalytic  deprotection  of  acetals  and  ketals,
[4,5] 
TBMDS  and  TIPS  groups.
[6]  The  mechanism  seems  to  proceed  through  radicals 
intermediate, but it’s not completely known. 
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    85        86 
Reagents and conditions: i) CAN, CH3CN/H2O, r.t.,2.30 h. 61 
 
Scheme 3.16: Reaction of deprotection of compound (84) to give compound (86). 
 
The 
1H-NMR spectrum proves that the compound is the one expected (86) since the 
broad peak of the amine is visible in Figure 3.16 at 5.8 ppm and the peaks of the 
methoxybenzyl group (previously present at7.2, 6.8, 4.5 and 3.8 ppm, Figure 3.16) 
are disappeared. 
 
 
Figure 3.16: 
1H-NMR in CDCl3 of the iodo-compound (86). 
 
The protection of the amide functionality of the iodo-compound (86) has been made 
via formation of the relative ethyl ether through triethyloxonium tetrafluoroborate, as 
shown in Scheme 3.17 achieving compound (87). The aim is to avoid the formation 
of enolate, possible side product in the reaction of coupling with the DKP (33, see 
chapter 4).  
HN
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I
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           86          87 
Reagents and conditions: i) Et2OBF3, DCM, r.t.,16 h. 62 
 
Scheme 3.17: Reaction of protection of the carbonyl. 
 
 
After  purification  in  chromatography  column  starting  material  was  recovered. 
Probably the reaction can be pushed further increasing the yield leaving the reaction 
stirring for more than 16 hours. 
 
 
3.4-  Conclusions 
 
The  side  chain  (87)  has  been  synthesised  with  the  aim  of  coupling  it  to  the 
diketopiperazine core (33), reaction that will be discussed in the next chapter. Iodine 
is fundamental for this reaction as it is a good leaving  group that is suitable for 
alkylating electropositive carbons, such as the one in the a position to the carbonyl 
of DKP (33). 
The methoxyphenyl ethyl group bonded to the nitrogen of the heterocycle (85) was 
selected due to its ease of cleavage via the CAN reaction. The final step in this 
synthetical strategy was the protection of the amide carbonyl functional group (86) 
which avoids the possible formation of the enolate (79) during the coupling. The 
synthesis  of  the  iodo-compound  (79)  has  been  successful,  but  further  research  is 
necessary to improve the yields, especially the cyclisation and the protection of the 
carbonyl (87).  
 
3.5-  Experimental section 
 
  - (E)-Methyl-3-(methylamino)acrylate (63)  
   
O
OCH3
N
H
H3C
 
 63 
 
To a stirred solution of methyl propiolate (40, 2.5 mL, 29.9 mmol) in anhydrous THF 
(15 mL) was added methyl amine (62, 16.5 mL, 2M, 33 mmol) at -10 °C. After 2 
hours the reaction was concentrated in vacuo. to yield a viscous yellow liquid (63) in 
75 % yield, which was used in subsequent reactions without further purification. Rf: 
0.36, (Cyclohexane:EtOAc, 50:50); δH (400 MHz; CDCl3): 7.60-7.53 (m, 1H, CHN, 
diasteroisomers Z) and 6.63-6.56 (m, 1H, CHN, diasteroisomers E), 4.74 (d, 1H, J = 
13.2 Hz, CHC, diasteroisomers Z) and 4.49 (d, 1H, J = 8.0 Hz, CHC, diasteroisomers 
E), 4.55 (br. s, 1H, NH), 3.67 (s, 3H, CH3O, diasteroisomers Z) and 3.64 (s, 3H, 
CH3O, diasteroisomers E); 2.97 (d, 3H, J = 5.0 Hz, CH3N, diasteroisomers Z) and 
2.78 (d, 3H, J =5.1 Hz, CH3N, diasteroisomers E); δC (100 MHz, CDCl3): 171.2 (CO, 
diasteroisomers Z), 169.9 (CO, diasteroisomers E), 154 (CHCO, diasteroisomers Z), 
150  (CHCO,  diasteroisomers  E),  85.0  (CHNH,  diasteroisomers  Z),  81.4(CHNH, 
diasteroisomers E), 50.4(CH3O, diasteroisomer E), 50.0 (CH3O, diasteroisomer Z), 
34.7  (CH3NH,  diasteroisomer  Z)  30.0  (CH3NH,  diasteroisomer  E);  HRMS: 
calculated for C5H9NO2 115.0633, found 115.0636. 
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- Methyl 1-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (64) 
 
N
H3C
O
O OCH3 
 
To a stirred solution of (E)-methyl-3-(methylamino)acrylate (63, 0.99 g, 8.6 mmol) 
in anhydrous THF (10 mL) under nitrogen was added acryloyl chloride (38, 0.77 mL, 
9.47 mmol).  After 5 hours reflux the reaction mixture was washed with saturated 
NaHCO3 (10 mL) before EtOAc (10 mL) was added.  The fractions were separated 
and the aqueous phase was extracted with EtOAc (4 x 20 mL).  The organic layers 
were combined, dried over MgSO4 and concentrated in vacuo to yield a crude yellow 
oil, purified by silica gel column chromatography (EtOAc:hexane, range 85:15 to 
70:30)  to  afford  the  bright  yellow  crystal  (64)  in  47%  yield.  Rf:  0.36, 
Cyclohexane:EtOAc, 50:50; δH (400 MHz; CDCl3): 7.27 (s, 1H, CH), 3.75 (s, 3H, 
CH3O), 3.15 (s, 3H, CH3N); 2.65-2.55 (m, 4H, CH2CH2); δC (100 MHz, CDCl3): 
170.0 (COO), 166.7 (CO), 140.8 (CHN), 108.3 (CHC), 51.5 (CH3O), 34.6 (CH3N), 
30.7  (CH2CO),  20.0  (CH2CH2);  mp:  74-76  °C;  HRMS:  calculated  for  C8H11NO3 
169.0739, found C8H11NO3 169.0739. 65 
 
-  Methyl 1-methyl-6-oxopiperidine-3-carboxylate (65) 
 
N
H3C
O
O OCH3  
 
To  a  stirred  solution  of  methyl  1-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-
carboxylate (64, 2.1 g, 12.4 mmol) in EtOH (30 mL) under nitrogen were added 
Na2CO3 (3.12 g, 37.3 mmol) and Pd/C (1.3 g, 12.2 mmol). The hydrogen was added 
as a gas through hydrogen balloon. The reaction was left overnight and the solid 
Pd/C was removed by filtration in fluted paper. The solution was concentrated in 
vacuo,  the  resulting  crude  oil  was  purified  by  silica  gel  column  chromatography 
(cyclohexane:EtOAc, 60:40) to afford a clear oil in 85 % yield. Rf: 0.15, EtOAc 
100%; δH (400 MHz; CDCl3) 3.73 (s, 3H, CH3O), 3.56-3.44 (m, 2H, CH2N), 2.96 (s, 
1H, CH3N), 2.88-2.80 (m, 1H, CH), 2.52 -2.46 (m, 2H, CH2CO), 2.42-2.35 (m, 2H, 
CH2CO), 2.18-2.12 (m, 2H, CH2CH2), 2.03-1.96 (m, 2H, CH2CH2); dC(100 MHz, 
CDCl3)  172.7  (COO),  169.0  (CO),  52.3  (CH3O),  50.5  (CH2N),  38.8  (CH), 
34.8(CH3N),  30.6  (CH2CO),  24.0  (CH2CH2);  HRMS:  calculated  for  C8H13NO3 
171.0895, found 171.0895. 66 
 
-  5-(hydroxymethyl)-1-methylpiperidin-2-one (66) 
 
N
H3C
O
OH  
 
To a stirring solution of methyl 1-methyl-6-oxopiperidine-3-carboxylate (65, 0.52g, 
2.9 mmol) in anhydrous THF (8 mL) under nitrogen, was added LiBH4 (2.9 mL, 5.8 
mmol) at -10 °C. The reaction was allowed to reach the room temperature and was 
stirred overnight.  Water and HCl 1M were added in order to quench the reduction 
agent  and  to  neutralise  the  solution.  Water  was  taken  off  at  the  freezing  drier 
machine  and  the  powder  obtained  was  purified  via  silica  gel  chromatographic 
column (MeOH:DCM 1:10) achieving a slightly yellow liquid in 60% yield. Rf: 0,43 
(MeOH:EtOAc 1:3); δH (400 MHz; CD3OD) 3.58-3.51 (m, 2H, CH2OH), 3.44-3.40 
(m, 1H, CH2N), 3.22-3.14 (m, 1H, CH2N), 2.94 (s, 3H, CH3N), 2.44-2.29 (m, 2H, 
CH2O), 2.10 -2.00 (m, 1H, CH), 1.91-1.86 (m, 1H, CH2CH2), 1.57-1.47 (m, 1H, 
CH2CH2); δc (100 MHz; CD3OD), 169.0 (CO), 52.3 (CH2N), 50.5 (CH2OH), 38.8 
(CH), 34.8 (CH3N), 30.6 (CH2O), 24.0 (CH2CH2); HRMS: calculated for C7H13NO2 
143.0946, found 143.0944. 67 
 
-  5-(iodomethyl)-1-methylpiperidin-2-one (68) 
 
N
H3C
O
I  
 
To a stirring solution of 5-(hydroxymethyl)-1-methylpiperidin-2-one (66, 0.2 g, 1.4 
mmol) in anhydrous pyridine (15 mL) was added slowly and at 0 °C mesyl chloride 
(0.21 mL, 1.82 mmol). After allowing the solution to reach the room temperature it 
was brought to reflux for 3 hours and concentrated in vacuo. The crude brown oil 
(0.25 g, 1.13 mmol) was dissolved in acetone (15 mL) and was added NaI (0.51 g, 
3.39 mmol). The solution was brought to reflux for 4 hours, the solvent was removed 
in vacuo, brine was added (10 mL) and the mixture was extracted with DCM (4 x 15 
mL).  The  crude  brown  oil  was  purified  by  silica  gel  chromatography  column 
(DCM:MeOH 10:1) achieving 62 % yield over two steps. Rf: 0,5 (MeOH:EtOAc 
1:3); δH (400 MHz; CDCl3) 3.59-3.49 (m, 1H, CH2I), 3.48-3.41 (m, 2H, CH2N), 
3.25-3.14 (m, 1H, CH2I), 2.96 (s, 3H, CH3N), 2.55-2.34 (m, 2H, CH2CO), 2.32-2.21 
(m, 1H, CH), 2.00-1.93 (m, 1H, CCH2C), 1.73-1.57 (m, 1H, CH2CH2); 
 δc (100 MHz; 
CDCl3)  169  (CO),  52.3  (CH2N),  50.5  (CH2I),  38.8  (CH),  34.8  (CH3N),  30.6 
(CH2CO),  24.0  (CH2CH2);  HRMS:  calculated  for  C7H12NOI  252.9964,  found 
252.9973. 68 
 
-   (E)-Methyl 3-(4-methoxybenzylamino)acrylate (80) 
 
O
OCH3
N
H
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The procedure was the same used to synthesise compound (63), employing methyl propiolate 
(40, 1.5 mL, 17.8 mmol) this time with 4-methoxybenzyl amine (39, 2.32 mL, 17.84 mmol) 
instead of methyl amine (62), achieving (E)-Methyl 3-(4-methoxybenzylamino)acrylate 
(80) as a white solid in 99 % yield. Rf: 0.35, Cyclohexane:EtOAc, 50:50; δH (400 
MHz; CDCl3) 8.07 (br. s, 1H, NH), 7.59-7.54 (dd, J = 13.3 Hz, J = 8.0 Hz, 1H, CH-
CO, diasteroisomers E ), 7.23-7.15 (m, 2H, Ph), 6.89-6.86 (m,2H, Ph), 6.71-6.65 (dd, 
J = 13.1 Hz, J = 8.1 Hz, 1H, CH-CO, diasteroisomers Z), 4.83-4.79 (d, J = 13.3 Hz, 
1H,  CH-N,  diasteroisomers  E),  and  4.54-4.52  (d,  J  =  8.1  Hz,  1H,  CH-N, 
diasteroisomers Z), 4.29-4.28 (d, J = 5.9 Hz, 2H, CH2-Ph, diasteroisomer Z), 4.13-
4.14 (d, J = 7.7 Hz, 2H, CH2-Ph, diasteroisomer E); 3.8 (t, J = 1.8 Hz, J = 3.79 Hz, 
3H,  CH3O),  3.66  (s,  3H,  CH3CO,  diasteroisomer  E),  3.64  (s,  3H,  CH3CO, 
diasteroisomer  Z);  δC  (100  MHz,  CDCl3)  171.1  (COO),  170.1  (CO),  159.3  (Ph), 
152.3 (CHNH), 130.6 (Ph), 128.7 (Ph), 114.3 (Ph), 86.6 (CHCO, disteroisomer E), 
82.6 (CHCO, disteroisomer Z), 55.4 (CH3OPh), 52.0 (CH3OCO) , 50.3 (CH2NH);. 
HRMS: calculated for C12H15NO3 221.1052, found 221.1043. 69 
 
-  Methyl  1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate 
(81) 
 
N
O
O OCH3
H3CO
 
 
The procedure followed is the same used to synthesise compound (64), using as starting 
material  acryloyl  chloride  (38,  1.59  mL,  19.6  mmol)  and  (E)-Methyl  3-(4-
methoxybenzylamino)acrylate  (80,  3.94g,  17.82  mmol)  achieving  after  silica  gel 
chromatography column (EtOAc:Cyclohexan from 15:85 to 20:80) a yellow oil in 33 % 
yield. Rf: 0.58, Cyclohexane:EtOAc, 50:50;.; δH (400 MHz; CDCl3) 7.27 (s, 1H, 
CH), 7.21-7.18 (d, J = 10.2 Hz, J = 8.2 Hz, 2H, Ph), 6.88-6.85 (m, 2H, Ph), 4.67 (s, 
2H, CH2Ph) 3.79 (s, 3H,CH3O), 3.72 (s, 3H, CH3N); 2.62 (s, 4H, CH2CH2); δC (100 
MHz, CDCl3) 169.9 (COO), 167.0 (CO), 159.3 (Ph), 139.5 (CHN), 129.3 (Ph), 128.7 
(Ph), 114.2 (Ph), 108.9 (CHCO), 55.5 (CH2Ph), 51.8 (CH3OPh), 49.5 (CH3OCO), 
30.9 (CH2CO), 20.2 (CH2CH2); HRMS: calculated for C15H17NO4 275.1158; found 
C8H11NO3 275.1171. 70 
 
-  Methyl 1-(4-methoxybenzyl)-6-oxopiperidine-3-carboxylate (82) 
 
N
O
O OCH3
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The  procedure  used  to  achieve  methyl  1-(4-methoxybenzyl)-6-oxopiperidine-3-
carboxylate (82) was the same used to synthesise compound (65), but starting from 
methyl  1-(4-methoxybenzyl)-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate  (81, 
1.59 g, 5.7 mmol). The obtained clear oil was purified by silica gel chromatography 
column  (EtOAc  100%)  in  86  %  yield.  Rf:  0.34,  EtOAc,  100%;  δH  (400  MHz; 
CDCl3) 7.20-7.19 (d, J = 7.0 Hz, 2H, Ph), 6.86-6.84 (d, J = 8.6 Hz, 2H, Ph), 4,65-
4,61 (dd, J = 14.4, Hz, 4.1 Hz, 2H, CH2Ph), 4,46-4,43 (dd, J = 14.4 Hz, 3.8 Hz, 2H, 
CH2Ph), 3.79 (s, 3H,CH3O), 3.66 (s, 3H, CH3N); 3.44-3.36 (m, 4H, CH), 2.80-2.72 
(m, 2H, CH2N), 2.61-2.55 (m, 1H, CH3OH), 2.49-2.42 (m, 2H, CH2CO), 2.14-2.10 
(m, 1H, CH2CH2), 2.02-1.94 (m, 1H, CH2CH2), δC (100 MHz, CDCl3) 172.8 (COO), 
169.0. (CO), 159.1 (Ph), 129.6 (Ph), 128.9 (Ph), 114.1 (Ph), 55.3 (CH3OPh), 52.3 
(CH2Ph), 49.6 (CH3O), 48.0 (CH3N), 39.1 (CH), 30.8 (CH2CO), 24.0 (CH2CH2); 
HRMS: calculated for C15H19NO4 277.1314, found 277.1325. 71 
 
-  5-(hydroxymethyl)-1-(4-methoxybenzyl)piperidin-2-one (83) 
 
N
O
OH
H3CO
 
 
The same procedure used to synthesise (66) has been used also for compound (83) 5-
(hydroxymethyl)-1-(4-methoxybenzyl)piperidin-2-one,  using  methyl  1-(4-
methoxybenzyl)-6-oxopiperidine-3-carboxylate  (82,  0.94  g,  3.4  mmol)  as  starting 
material, but this time with a different work out. Water and HCl 1M were added. The 
organic layer was separated and the water was extracted with EtOAc (4 x 20 mL). 
The organic layers were combined and dried over MgSO4, concentrated in vacuo and 
purified  by  silica  gel  chromatography  column  (EtOAc:MeOH  95:5)  obtaining  a 
slightly  yellow  oil  in  85  %  yield.  Rf:  0,4  (MeOH:EtOAc  5:95);  δH  (400  MHz; 
CD3OD) 7.20-7.18 (d, J = 8.6 Hz, 2H, Ph), 6.86-6.83 (d, J = 8.5 Hz, 2H, Ph), 4.52 (s, 
2H, CH2-Ph), 3.79 (s, 3H, CH3OPh), 3.60-3.56 (m, 2H, CH2N), 3.51-3.46 (m, 2H, 
CH2N), 3.33-3.29 (m, 1H, CH2O), 3.02-2.96 (m, 1H, CH2O), 2.58-2.51 (m, 2H, CH2-
CO),  2.46-2.37  (m,  2H,  CH2-CO),  2.05-1.98  (m,  1H,  CH),  1.91-1.86  (m,  2H, 
CH2CH2), 1.56-1.46 (m, 2H, CH2CH2); δC (100 MHz; CD3OD) 169.6 (CO), 158.7 
(Ph),  129.4  (Ph),  129.3  (Ph),  114.0  (Ph),  64.7  (CH3OPh),  55.1  (CH2Ph),  49.8 
(CH2OH),  49.1  (CH2N),  36.2  (CH),  31.1  (CH2CO),  23.8  (CH2CH);  HRMS: 
calculated for C14H19NO3 249,1365, found 249.1376. 72 
 
-  5-(iodomethyl)-1-(4-methoxybenzyl)piperidin-2-one (85) 
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To a stirring solution of 5-(hydroxymethyl)-1-(4-methoxybenzyl)piperidin-2-one (83, 
0.7  g,  2.8  mmol)  in  anhydrous  DCM  (10  mL)  were  added  TEA  (0,61  mL,  4.35 
mmol) and Mesyl chloride (0.27 mL, 3.48 mmol), after cooling down the solution to 
-10 °C. The reaction was left over night, quenched with water and the organic layer 
was separated. Brine (10 mL) was added and the aqueous phase was washed with 
EtOAc  (5  x  20  mL).  The  organic  layers  were  combined,  dried  over  MgSO4  and 
concentrated in vacuo achieving a dark yellow oil in 93 % yield. Compound (84) was 
dissolved  in  acetone  (10  mL)  and  NaI  (1  g,  6.75  mmol)  was  added.  The  reaction  was 
refluxed for 2 hours and then stirred overnight; the day after it was refluxed for further two 
hours. Acetone was removed in vacuo, water was added (10 mL) and extracted with EtOAc 
(5 x 20 mL). The organic layers were combined, dried over MgSO4 and concentrated in 
vacuo. The crude  orange oil  was  purified by  silica gel  chromatography  column  (EtOAc 
100%) achieving a dark yellow oil with a yield of 80 %. Rf: 0,65 (MeOH:EtOAc 5:95);  
δH (400 MHz; CD3OD) 7.22-7.20 (d, J= 8.6 Hz, 2H, Ph), 6.88-6.86 (d, J = 8.6 Hz, 
2H, Ph), 4.62-4.47 (q, J = 14.4 Hz, 2H, CH2Ph), 3.81 (s, 3H, CH3OPh), 3.38-3.34 
(m, 2H, CH2NH), 3.14-3.06 (m, 1H, CH2I), 2.99-2.94 (m, 2H, CH2NH), 2.61-2.54 
(m, 2H, CH2CO), 2.50-2.41 (m, 2H, CH2CO), 2.06-1.99 (m, 2H, CH and CH2CH2), 
1.66-1.55 (m, 1H, CH2CH2); δC (100 MHz; CD3OD) 169.0 (CO), 159.0 (Ph), 129.6 
(Ph), 128.9 (Ph), 114.0 (Ph), 55.2 (CH3OPh), 52.0 (CH2N), 49.4 (CH2Ph), 36.1 (CH), 
30.7  (CH2CO),  28.0  (CH2  CH2),  7.9  (CH2I);  HRMS:  calculated  for  C14H18INO2 
359,0382, found 359,0391. 73 
 
-  5-(iodomethyl)piperidin-2-one (86) 
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To a stirring solution of 5-(iodomethyl)-1-(4-methoxybenzyl)piperidin-2-one (85, 0.2 
g, 0.56 mmol) in CH3CN/H2O 3:2 (10 mL) was added cerium ammonium nitrate 
(CAN, 0.92 g, 1.68 mmol). The reaction was stirred for 2:30 hours. CH3CN was 
removed in vacuo, and the aqueous phase was washed with DCM (5 x 10 mL). The 
organic layers were combined, dried over MgSO4, concentrated in vacuo and purified 
in  silica  gel  chromatography  column  (from  cyclohexan:EtOAc  20:80  to 
EtOAc:MeOH  95:5)  in  a  yield  of  41  %  as  a  pale  brown  solid.  Rf:  0,24 
(MeOH:EtOAc 5:95); δH (400 MHz; CD3OD) 5.80 (br. s, 1H, NH), 3.54-3.51 (d, J = 
12.2 Hz, 1H, CH2N), 3.24-3.13 (m, 2H, CH2I), 3.10-3.06 (m, 1H, CH2N), 2.51-2.34 
(m, 2H, CH2CO), 2.08-2.00 (m, 2H, CH and CH2CH2), 1.70-1.60 (m, 1H, CH2CH2); 
δC (100 MHz; CD3OD) 171.3 (CO), 47.8 (CH2N), 35.6 (CH), 29.9 (CH2CO), 27.7 
(CH2 CH2), 7.8 (CH2I); mp: 90-92 °C; HRMS: calculated for C6H10INO 238,9807, 
found 238,9809. 
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-  6-ethoxy-3-(iodomethyl)-2,3,4,5-tetrahydropyridine (87) 
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To a stirring solution of Boron trifluoride triethyl etharate (0.1 mL, 0.79 mmol) in 
anhydrous  Et2O  (5  mL)  and  nitrogen  flow  epichlorohydrine  was  added  dropwise 
(0.05 mL, 0.63 mmol). The reaction was refluxed for one hour and after cooling it to 
room temperature, it was stirred for a further hour allowing the formation of the pale 
brown  salt  triethyloxonium  trifluoroborate.  Under  nitrogen  flux,  the  solvent  was 
filtered out and once the salt was dry compound (86, 0.87 g, 0.36 mmol) was added 
afrer been dissolved in anhydrous DCM (6 mL). The reaction was stirred over night, 
neutralized with a solution of Na2CO3 (8 mL). The organic layer was separated, the 
aqueous  phase  was  washed  with  EtOAc  (3  x  10  mL),  the  organic  phases  were 
combined, dried over MgSO4, concentrated in vacuo and purified through silica gel 
chromatography (EtOAc) obtaining a brown liquid in a yield of 32 % . Rf: 0.63 
(MeOH:EtOAc 5:95). 
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4.1-  Aim  
The aim of this last part of the project is the coupling between the DKP core (56c), 
and the novel side chain (68 and 87) described in Chapters 2 and 3 respectively, 
followed  by  the  hydrolysis  of  the  substituted  DKP  core  (56c)  in  an  effort  to 
synthesise amino acid (25). 
 
4.2-  Introduction 
 
The treatment of bacterial or fungal infections is an ongoing challenge in modern 
medicine.    Both  fungi  and  mammals  are  eukaryotes  and  so  achieving  a  good 
selective  toxicity  is  not  easy  or  straightforward.    For  this  reason  the  enzymatic 
pathways leading to the formation of fungal and bacterial cell walls have became an 
important target for drugs. 
An example of such a target is L-glutamine (15), involved in the transfer of ammonia 
in the isomerisation of Fru-6-P (16) to Glu-6-P (17), a reaction catalysed by GlcN-6-
PS, shown previously in Scheme 1.3.
[1] 
This reaction is the first step in the pathway leading to the formation of the activated 
form of N-acetyl-D-glucosamine, namely 5’-diphospho-N-acetyl-D-glucosamine (19, 
UDP-GlcNAc, Figure 11).  
This nucleotide sugar is essential for the biosynthesis of biomacromolecules such as 
bacteria peptidoglycan, fungal chitin and mammalian glycoproteins. 
Many bacteria use the products of the biosynthetic pathway to synthesise hyaluronic 
acid capsules which surrounds their cell walls and which are connected with the 
infectious process.
[2,3]  
The absence of GlcN-6-PS has different consequences in human beings than in either 
fungi or bacteria.  Mammals rapidly express this enzyme with a long half life and the 
relatively long life of mammalian cells means that a deficiency of the enzyme has no 
lasting  effects.    Conversely,  the  absence  of  GlcN-6-PS  can  be  lethal  to  bacteria 
resulting in morphological changes and ultimately cell lysis.
[4]  These behavioural 
differences allow for a selective toxicity.  GlcN-6-PS has already been a target for a 
potential drug to be used in the treatment of diabetes,
[5] bowel disease
[6] and fungal 
infections.
[7] 77 
 
Considering that high specificity is a fundamental aspect of a rational drug design, it 
is  important  to  understand  the  mechanism  by  which  an  inhibitor  operates  and  to 
determine  the  crucial  functionalities  and  interactions  to  achieve  selectivity  and 
optimal activity. 
 
4.3-  Synthetic approach and discussion 
 
The coupling between the substituted benzyl DKP core (56c) and the side chain (68) 
was made via alkylation using lithium bis(trimethyl)silyl amide (LHMDS, 90) as 
base. The metallation of the DKP (56c) was carried out in THF at -20°C and then 
quenched with the iodo-derivative (68), as shown in Scheme 4.1, but unfortunately 
no coupling product (89) was recovered.  TLC analysis of the crude reaction mixture 
showed  four  different  spots,  the  two  most  intense  corresponded  to  the  starting 
materials recovered after silica gel chromatography column. 
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ii)
    
        56c        68                 89 
Reagents and conditions: i) anhydrous THF, LHMDS, -78 °C, 1 h; ii) anhydrous THF, 3-((1-methyl-
6-oxopiperidin-3-yl)methyl)-1,4-bis((S)-1-phenylethyl)piperazine-2,5-dione (68), -78 °C, 2 h. 
Scheme 4.1: Reaction investigating the alkylation of the DKP (56c) with iodo-derivative (68), in an 
effort to synthesise substituted DKP (89). 
 
The same reaction was attempted using an alternative, less hindered base, namely 
butyl lithium (BuLi), but this lead to the same result.   78 
 
It is difficult to understand the reason why this coupling was unsuccessful.  Similar 
reactions with other iodo-derivatives have been performed successfully many times 
in the Paradisi laboratory (Figure 3.8). 
The general mechanism of the alkylation of DKP (33) is described in Scheme 4.2.  
The first step, the deprotonation of the DKP (33) proceeds very quickly, typically 
within 30 minutes and 1 hour.  The second step, the alkylation, takes between 1 and 2 
hours.  In this instance, the coupling of the DKP (56c) with iodo- derivative (68), the 
reaction was left overnight to see if any production of product could be detected, 
unfortunately nothing was observed. 
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Scheme 4.2: Mechanism of alkylation of DKP (33) with LHMDS (90). 
 
The protons in the a position to the carbonyl carbon of the iodo-compound (68) are 
very reactive and so in an effort to avoid the metallation at this site, it was decided to 
attempt to couple a substituted benzyl DKP (56c) with an alternative iodo-derivative 
(87)  in  which  the  carbonyl  functionality  was  protected,  as  shown  in  Scheme 
33  90  78  91 
78 
92 
93 79 
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        56c         87              94 
Reagents and conditions: i) anhydrous THF, LHMDS, -78 °C, 1 h. ii) anhydrous THF, 3-((6-ethoxy-
2,3,4,5-tetrahydropyridin-3-yl)methyl)-1,4-bis((S)-1-phenylethyl)piperazine-2,5-dione (87), 
 -78 °C, 2 h. 
Scheme 4.3:  Reaction investigating the alkylation of the DKP (56c) with iodo- derivative (87), in an 
effort to synthesise substituted DKP (94). 
 
TLC analysis of the reaction mixture after 2 and even after 16 hours showed only 
starting materials, which were recovered after silica gel chromatography column. 
 
 
4.4-  Conclusions 
 
It is important to understand the mechanisms by which anticapsin (12) enters in the 
active site of GlcN-6-PS and inhibits this enzyme. These kind of studies are useful in 
the development  of antimicrobial drugs.  In the heterocyclic analogue of anticapsin 
(25), which has been the target molecule of this research project, the ketone moiety 
has been replaced with an amide functionality. It is envisaged that any attack on the 
carbonyl  moiety  and  the  subsequent  hydrolysis  to  form  the  hydrate  (24)  are  less 
likely in the heterocyclic analogue of anticapsin (25), compared to anticapsin (12).  
This analogue (25) could help to understanding whether the proposed mechanism, 
previously shown in Scheme 1.4, is correct.
[8] 
In order to synthesise the target molecule (25) the coupling of substituted benzyl 
diketopiperazine (56c) and two different kinds of iodo-dervied side chains (68 and 80 
 
87) were investigated.  DKPs (33) are very interesting because of their ability to 
generate different kinds of amino acids after alkylaion and hydrolysis. Unfortunately 
the alkylations were unsuccessful and only starting materials were recovered. 
 
 
4.5-  Future work 
 
Further investigations are required to explain why these reactions failed and to find 
alternative means by which to synthesise alkylated DKPs.   
Upon production of the alkylated DKPs (89 and 94) from the coupling of a side chain 
to the DKP core (56c) a few subsequent steps shall be required to obtain the desired 
amino  acid  (25),  shown  in  Scheme  4.4,  and  test  its  biological  activity  as  an 
antimicrobial  agent.  Depending  on  the  outcome  of  these  biological  tests  it  is 
envisaged that a series of different antaicapsin analogues will be synthesised in a 
similar  manner,  via  coupling  of  a  side  chain  with  the  DKP  core,  for  further 
investigations. 
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          94        35                  25 
Scheme 4.4: Hydrolysis of the alkylated DKP (94) to produce 2-ammonio-3-(6-oxopiperidin-3-
yl)propanoate (25) via 2-ammonio-3-((1R,6R)-2-oxo-7-oxa-3-aza-bicyclo[4.1.0]heptan-5-
yl)propanoate (35). 
 
 
 
 81 
 
4.6-  Experimental section 
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-  3-((1-methyl-6-oxopiperidin-3-yl)methyl)-1,4-bis((S)-1-
phenylethyl)piperazine-2,5-dione (89) 
 
To a stirred solution of DKP (56c, 0.2 g, 1.02 mmol) in anhydrous THF (15 
mL) under nitrogen at -20 °C was added LHMDS (0.62 mL, 1.02 mmol) 
dropwise.  After  1  hour  the  reaction  was  cooled  to  -78  °C  before  5-
(iodomethyl)-1-methylpiperidin-2-one  (68,  0.16  g,  1.02  mmol)  was  added. 
After  stirring  overnight  water  (10  mL)  was  added  and  aqueous  phase 
extracted with EtOAc (4 x 15 mL). The combined organic layers were dried 
over  MgSO4,  concentrated  in  vacuo  and  purified  via  silica  gel 
chromatography column (EtOAc/Cyclohexane from 10:90 to 50:50) to isolate 
only the starting materials (0.13 g of DKP 56c and 0.094 of iodo-compound 
68) and minute quatities of two undentified compounds. 
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-  3-((6-ethoxy-2,3,4,5-tetrahydropyridin-3-yl)methyl)-1,4-bis((S)-1-
phenylethyl)piperazine-2,5-dione (94) 
 
N
N
O
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Ph
Ph
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O
 
 
To a stirred solution of DKP (56c, 0.087 g, 0.27 mmol) in anhydrous THF (5 
mL)  under  nitrogen  at  -20  °C  was  added  LHMDS  (0.3  mL,  0.3  mmol) 
dropwise.    After  1  hour  the  reaction  was  cooled  to  -78  °C  before  iodo 
compound NAME!(97, 0.072 g, 0.27 mmol) was added.  After two hours 
water (10 mL) was added and the aqueous phase was extracted with EtOAc 
(4  x  15  mL).  The  combined  organic  layers  were  dried  over  MgSO4, 
concentrated  in  vacuo  and  purified  via  silica  gel  chromatography  column 
(EtOAc/Cyclohexane  from  10:90  to  50:50)  to  isolate  only  the  starting 
materials (0.076 g of DKP 56c and 0.026 of iodo-compound 68). 
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